Back

Notification report


Full notification file


General information

Notification Number
B/ES/20/22

Member State to which the notification was sent
Spain

Date of acknowledgement from the Member State Competent Authority
02/10/2020

Title of the Project
Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Severe Hemophilia A (FVIII:C≤1%)

Proposed period of release:
01/03/2021 to 31/05/2021

Name of the Institute(s) or Company(ies)
Pfizer, Inc., 235 East 42nd Street, New York, NY 10017-5755, USA.;


3. Is the same GMO release planned elsewhere in the Community?
Yes:
Belgium; France; Greece; Italy; Sweden; Czech Republic;

Has the same GMO been notified elsewhere by the same notifier?
No

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
Genus: Dependoparvovirus
Species: Recombinant adeno-associated viral vector derived from naturally occurring AAV6 serotype


Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
-DependoparvovirusAdeno-associated dependoparvovirus-AAV6-

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known